This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.
Study Type
OBSERVATIONAL
Enrollment
1,037
Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
Novo Nordisk Investigational Site
Dublin, Ireland
Novo Nordisk Investigational Site
London, United Kingdom
Number of serious adverse drug reactions (SADRs), including major hypoglycaemic events
Time frame: Weeks 0-26
Number of serious adverse events (SAEs)
Time frame: Weeks 0-26
Number of all adverse events (AEs)
Time frame: Weeks 0-26
Number of all hypoglycaemic events
Time frame: In the 4 weeks preceeding week 26
Weight change
Time frame: Week 0, week 26
Glycosylated haemoglobin (HbA1c)
Time frame: Week 26
Variability in fasting plasma glucose (FPG)
Time frame: Week 26
Average plasma glucose level
Time frame: Week 26
Quality of Life as assessed by a treatment satisfaction questionnaire
Time frame: Week 26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.